U.S FDA Approves Mirdametinib (Gomekli, SpringWorks) for Adult and Pediatric Patients With NF1-PN
The U.S. Food and Drug Administration (FDA) approved mirdametinib (Gomekli, SpringWorks) for the treatment of adult and pediatric patients aged two and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) that are not amenable to complete resection. Gomekli is an oral, small molecule MEK inhibitor. NF1 is a genetic disorder that […]